The 5th of Dec presentation was the first time Stamler said that there is a possibility to get ATH434 to the market after these phase 2 studies. He has been telling us before that after these studies there will be ph3. He is so careful about what he says.
The other new thing was that now the target sales of ATH434 for MSA patients is 1B, not 750M as earlier.
Peter Marks in FDA: accelerated approvals for rare diseases, page-6
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $20 | 3.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 33059984 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 16203558 | 24 |
View Market Depth
| Last trade - 10.00am 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 10.0 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.6¢ | 0.5¢ | 140816 | ||
| Last updated 11.48am 29/05/2024 ? | |||||
| ATH (ASX) Chart |